

IIIM-017:

It is a follow up lead molecule based on bicyclic nitroimidazole structure with potent anti-TB activity. IIIM-017 is a novel nitroimidazole structure containing polar functionality and active against resistant, replicating as well as non-replicating M. tb. It has shown better aqueous solubility (20 µg/ml). It has also shown *in vivo* efficacy in intranasal model of mice (1.28 log CFU reduction at 100 mg/kg). It is metabolically stable in RLM (99% remaining after 30 minute). It is also quite safe in Ames test. This lead is presently under IND-enabling studies.